Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + dexamethasone versus pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
NL-OMON48607Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in multiple myeloma (MM) comparing Ixazomib + dexamethasone with Pomalidomide + dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started Feb 2018; status: completed.
02
Drugs
ixazomibpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON48607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48607.